Related Experiment Video

Updated: Oct 29, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

Off-label use of aducanumab for cerebral amyloid angiopathy

Steven M Greenberg1, Charlotte Cordonnier2, Julie A Schneider3

  • 1Haemorrhagic Stroke Research Program, J Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114 USA.

The Lancet. Neurology
|July 8, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice08:17

Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice

Published on: February 15, 2019

38.2K
Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

12.9K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
428
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
901